Cellaviva Competitors

CBR is the world's largest cord blood and cord tissue bank. Cord Blood is rich in Stem Cells that are unique to the newborn and family. Cryopreservation of the cells has been called a type of 'biological insurance' because the stem cells are then available for use in medical treatments involving cancers and blood and immune disorders. The stem cells are an exact match for the newborn and have a higher likelihood of use in siblings. Diseases treated include leukemia, lymphoma, aplastic anemia and more than 75 other conditions amenable to stem cell transplant. New directions with cord blood stem cells include regenerative medicine for cerebral palsy and hearing loss.

Genea Biocells is a neuromuscular disease-focused company based on a proprietary technology platform for the accelerated development of drugs to treat neuromuscular diseases - typically rare orphan diseases that present an area of particularly high unmet medical need with patients in many cases being children for which no treatment options exist. Genea Biocells developed a proprietary skeletal muscle differentiation method used to generate disease-affected skeletal muscles for disease modeling and drug screening in ways not possible using other methods. Genea Biocells’ screening approach makes use of a highly curated repurposed chemical library of compounds with favorable toxicity profiles, paving an accelerated path for regulatory approval of lead compound hits. This drug development platform led to our current lead programs for facioscapulohumeral dystrophy (FSHD) and spinal muscular atrophy (SMA) as well as discovery-stage programs for Kennedy's disease, LAMA2 congenital muscular dystrophy, and congenital myotonic dystrophy. Genea Biocells is based in San Diego, California and originated from the Australian Genea group, a public, unlisted company that has been operating world leading IVF clinics since 1985.

Our Mission: To provide the highest-quality stem cell preservation service and care to our patients, families, and their physicians. We at ViaCord believe these words are much more than just a promise. They are the commitment we live by. Our Origins: ViaCord was established in 1993 to give expectant parents an opportunity to bank their children's cord blood with comfort and security. Prior to launching our Cord Blood Banking Service, ViaCord conducted extensive research and validation studies to set high standards regarding the collection, processing, and storage of cord blood. ViaCord worked closely with the following institutions during our development: * Obstetrics Program at Brigham and Women's Hospital in Boston, MA * The Christ Hospital in Cincinnati, OH * The University of Cincinnati's Hoxworth Blood Center, OH ViaCord's headquarters are located in Cambridge, Massachusetts; a recognized global hub of biotechnology. All cord blood collections are processed and stored at our cord blood storage facility outside of Cincinnati.